Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.32 |
| ▸ | JAK1 | P23458 | 10/20 | 0.32 |
| ▸ | JAK3 | P52333 | 10/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921770 | 0.90 | SMN1; SMN2 (0.42) | POLBSMN1; SMN2LMNAMEN1MAPK1 | |
| SCHEMBL9918549 | 0.84 | JAK1 (0.32) | JAK2JAK1JAK3 | |
| SCHEMBL9918552 | 0.79 | HTT (0.39) | JAK2JAK1JAK3POLBLMNA | |
| SCHEMBL9921777 | 0.78 | JAK1 (0.33) | JAK2JAK1JAK3ALDH1A1 | |
| SCHEMBL9918554 | 0.75 | PDE3B (0.40) | JAK2JAK1JAK3MAP3K11 | |
| SCHEMBL9921664 | 0.70 | MAP3K11 (0.41) | JAK2JAK1JAK3LMNAMAP3K11 | |
| SCHEMBL9918548 | 0.69 | JAK2 (0.36) | JAK2JAK1JAK3SMN1; SMN2MAP3K11 | |
| SCHEMBL9918533 | 0.69 | MAP3K11 (0.41) | JAK2JAK1JAK3POLBSMN1; SMN2 | |
| SCHEMBL9918550 | 0.69 | PRKCA (0.30) | MAP3K11 | |
| SCHEMBL9921780 | 0.67 | ALDH1A1 (0.47) | JAK2JAK1JAK3SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.